Daniel Morgensztern, MD

Medical Oncologist

Daniel Morgensztern

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Lung cancer

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 2001: American Board of Internal Medicine, Internal Medicine
  • 2004: American Board of Internal Medicine, Medical Oncology

Training

  • 1996 - 1998: Resident, Internal Medicine and Hematology, State University of Rio de Janeiro, Brazil
  • 1998 - 2001: Resident, Internal Medicine, University of Miami-Jackon Memorial Hospital, Miami, FL
  • 2001 - 2004: Fellow, Hematology and Oncology, University of Miami-Jackson Memorial Hospital, Miami, FL

Education

  • 199: MD, Fundação Técnico-Educational Souza Marques, Rio de Janeiro, Brazil

Research & Selected Publications

Research Interest

Main clinical and translational research interests are in the development of new Phase II clinical studies for patients with lung cancer

Research Publications

PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials
Authors:

Booth A, Hillman S, Laumann K, one or more additional authors omitted Morgensztern D, Mandrekar SJ

Journal & Year:

J Thorac Oncol | 2026

Erratum: Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer
Authors:

Ben-Shachar R, Nadhamuni K, Raez LE, one or more additional authors omitted Morgensztern D

Journal & Year:

JCO Oncol Pract | 2026

Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond
Authors:

Wermke M, Gambardella V, Kuboki Y, one or more additional authors omitted Morgensztern D

Journal & Year:

J Clin Oncol | 2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer
Authors:

Park W, Kasi A, Spira AI, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Goldman JW

Journal & Year:

N Engl J Med | 2026

Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Authors:

Riely GJ, Wood DE, Aisner DL, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Hang L

Journal & Year:

J Natl Compr Canc Netw | 2026

Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer
Authors:

Ben-Shachar R, Nadhamuni K, Raez LE, one or more additional authors omitted Morgenstzern D

Journal & Year:

JCO Oncol Pract | 2026

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Authors:

Johnson ML, Smit EF, Felip E, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Riely GJ

Journal & Year:

J Clin Oncol | 2025

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report
Authors:

Riely GJ, Ahn MJ, Clarke JM, one or more additional authors omitted Morgensztern D, one or more additional authors omitted Johnson BE

Journal & Year:

J Thorac Oncol | 2025